Westlake Chemical Corporation (NYSE: WLK) announced tday that it has submitted a proposal to acquire all of the outstanding shares of Axiall Corporation (NYSE: AXLL) for $20.00 per share (comprised of $11.00 in cash and 0.1967 of a Westlake share, which represented a value of $9.00 based on Westlake's closing price on January 22, 2016, the last trading day before Westlake made its proposal).
Showing posts with label profits. Show all posts
Showing posts with label profits. Show all posts
Friday, January 29, 2016
Why $GIMO is UP 16% #AfterHoursGainers @ $25.75 ?
Gigamon Inc (NASDAQ:GIMO) announced its quarterly earnings results on Thursday. The company reported $0.29 EPS for the quarter, topping the Zacks’ consensus estimate of $0.23 by $0.06, Market Beat reports. The company earned $67 million during the quarter, compared to analysts’ expectations of $62.76 million. During the same period last year, the firm earned $0.18 earnings per share. Gigamon’s revenue for the quarter was up 30.8% on a year-over-year basis.
Thursday, January 28, 2016
Why $AMDA is UP 30% #Realtime @ $2.50 ?
SALT LAKE CITY, Jan. 28, 2016 (GLOBE NEWSWIRE) -- Amedica Corporation (AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, is pleased to announce all four submissions to the Orthopaedic Research Society (“ORS”) Annual Meeting were accepted for presentation occurring March 5-8, 2016 in Orlando, Florida.
$UA Revenue Rises 31% #BeforeBell @ $77.25 UP 13%
Under Armour UA +1.47% profit and revenue surged in the fourth quarter, propelled by growing footwear sales, and prompting the company to offer a better-than-expected outlook.
Investors cheered the strong results and sent shares up 14% in pre-market trading.
Why $NEOS is UP 60% #PreMarketGainers @ $15.00 ?
DALLAS and FORT WORTH, Texas, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NEOS), a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product candidates for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that the U.S. Food and Drug Administration (FDA) approved Adzenys XR-ODT™ for the treatment of ADHD in patients six years and older. With this approval, Adzenys XR-ODT is the first and only extended-release orally disintegrating tablet (ODT) for the treatment of ADHD.
Why $RWLK is UP 14% #AfterHoursGainers @ $11.00 ?
Wall Street consensus is expecting that ReWalk Robotics Ltd (NASDAQ:RWLK) will report earnings of $-0.56 per share when the firm next issues their quarterly results. According to Zacks, the firm should release their report on or around 2016-02-11. This is based on the latest information available.
Wednesday, January 27, 2016
Why $FCX is UP 11% #Realtime @ $4.65 ?
NEW YORK (TheStreet) --Freeport-McMoRan (FCX -Get Report) stock is soaring by 16.79% to $4.91 in afternoon trading on Wednesday after pledging to reduce a debt load that exceeded $20 billion in the third quarter.
Why $FATE is UP 17% #PreMarketGainers @ $2.90 ?
Fate Therapeutics, Inc. (NASDAQ: FATE) announced today the U.S. Food and Drug Administration (FDA) has cleared the Company's investigational new drug (IND) application for ProTmune, a programmed cellular immunotherapy consisting of donor-sourced mobilized peripheral blood cells which have been functionally modulated using two small molecules. The IND is now active and Fate Therapeutics plans to initiate a multi-center, randomized, controlled Phase 1/2 clinical trial in adult patients with hematologic malignancies undergoing mobilized peripheral blood (mPB) hematopoietic cell transplantation (HCT) in mid-2016.
Tuesday, January 26, 2016
Why $CETX is UP 15% #BeforeBell @ $2.59 ?
FARMINGDALE, N.Y., Jan. 26, 2016 /PRNewswire/ -- Cemtrex (CETX), a diversified industrial and manufacturing leader, announced today that the company has received new orders in excess of $8 Million over the last two months across its Industrial Products and Services Group and Electronics Manufacturing Services Group.
Why $FMER is UP 24% #PreMarketGainers @ $19.00 ?
Huntington Bancshares Inc (HBAN.O) said on Tuesday it has agreed to buy Ohio-based FirstMerit Corp (FMER.O) for about $3.4 billion in a cash-and-stock deal.
Huntington expects the deal, which would combine two of Ohio's midsize banks, to add to its earnings per share in 2017, excluding one-time merger-related expenses.
Why $EVOL is UP 8% #PreMarketGainers @ $5.55 ?
ENGLEWOOD, CO--(Marketwired - Jan 26, 2016) - Evolving Systems, Inc. (NASDAQ : EVOL ), a leader in real-time activation, analytics and marketing for connected mobile devices, today announced that another wireless operator in Africa has selected the Company's Dynamic SIM Allocation™ (DSA) solution. The operator is part of a major multinational telecom group, and this is Evolving Systems' seventh order within the group.
Why $S is UP 15% #PreMarketGainers @ $2.90 ?
Sprint Corp. (NYSE: S) reported Q3 EPS of ($0.21), versus ($0.60) reported last year. Revenue for the quarter came in at $8.1 billion versus the consensus estimate of $8.69 billion.
Adjusting for the aforementioned severance and exit costs and impairment charge, net loss would have improved by approximately $300 million year-over-year, or $0.08 per share.
Why $PETX is UP 12% #AfterHoursGainers @ $3.55 ?
LEAWOOD, Kan., Jan. 25, 2016 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the Company filed an administrative New Animal Drug Application (NADA) with the Food and Drug Administration's Center for Veterinary Medicine (CVM) for Galliprant® for the control of pain and inflammation in dogs with osteoarthritis. The Animal Drug User Fee Act (ADUFA) date for approval is set for March 25. Aratana anticipates commercial availability of Galliprant to veterinarians in fall 2016.
Why $RLYP is UP 10% #AfterHoursGainers @ $21.50 ?
Relypsa, Inc. (NASDAQ: RLYP) announced results from 12 Phase 1 studies in healthy volunteers evaluating potential drug-drug interactions between Veltassa for oral suspension and 12 drugs that had previously demonstrated binding in in vitro tests. When Veltassa was administered at the same time as the drugs being tested, there was no clinically meaningful reduction in absorption for nine of the 12 drugs. Three drugs showed reduced absorption when they were co-administered with Veltassa, however, when dosing of Veltassa and these drugs was separated by three hours, no reduction in absorption was observed.
Monday, January 25, 2016
#NEWS: Why $WPZ was UP 4% @ $22.14 ?
Shares of Williams Partners L.P. (NYSE:WPZ) saw unusually-strong trading volume on Monday following a dividend announcement from the company,AnalystRatings.NET reports. Approximately 3,539,725 shares were traded during mid-day trading, a decline of 10% from the previous session’s volume of 3,927,790 shares.The stock last traded at $23.27 and had previously closed at $21.45.
Why $ENOC is UP 80% #Realtime @ $7.50 ?
The long-awaited decision is being celebrated by tech innovators and environmentalists.
The Supreme Court has ruled in favor of technology competition and innovation in how energy customers are compensated for reducing their electricity consumption.
Why $CASI is UP 32% #Realtime @ $1.10 ?
By: OCTASTAFF
Sparkle Byte Ltd New Position in CASI Pharmaceuticals Inc (NASDAQ:CASI)
Sparkle Byte Ltd has filled a SC 13D form regarding Casi Pharmaceuticals, Inc 1.13 +0.30 36.33%
CASI Pharmaceuticals Inc (NASDAQ:CASI) is a newly disclosed equity position and the filing was required due to activity on January 14, 2016. This most probably shows Sparkle Byte Ltd’s confidence and optimism in the future of the company.
Why Sparkle Byte Ltd Bought Casi Pharmaceuticals, Inc
Item 4. Purpose of Transaction
The Reporting Persons acquired the securities reported herein for investment purposes. The Reporting Persons may, from time to time, make additional purchases of Common Stockeither in the open market or in privately-negotiated transactions, depending upon the Reporting Persons’ evaluation of theIssuer’s business, prospects and financial condition, the market for the Common Stock, other opportunities available to theReporting Persons, general economic conditions, stock market conditions and other factors. Depending upon the factors noted above,the Reporting Persons may also decide to hold or dispose of all or part of their investments in the Common Stock or the Warrantand/or enter into derivative transactions with institutional counterparties with respect to the Issuer’s securities, includingthe Common Stock and debt securities convertible into the Common Stock.
Except as set forth in Item 3 and thisItem 4, the Reporting Persons have no present plans or proposals that relate to or that would result in any of the actions specifiedin clauses (a) through (j) of Item 4 of Schedule 13D of the Securities Exchange Act of 1934, as amended.
A copy of the Securities Purchase Agreementis filed as Exhibit 99.2 hereto, and is incorporated herein by reference.
Company Profile
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. Its product pipeline includes ENMD-2076, ZEVALIN, MARQIBO, CE Melphalan and 2ME2 (2-methoxyestradial). Its lead internal drug candidate is ENMD-2076 is a selective Aurora A and angiogenic kinase inhibitor for the treatment of cancer. ZEVALIN is indicated for patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma. MARQIBO is indicated for the treatment of Philadelphia chromosome-negative acute lymphoblastic leukemia. Captisol Enabled melphalan is being investigated and is intended to be used as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. 2ME2 (2-methoxyestradiol) is an orally active compound that has anti-proliferative, anti-angiogenic and anti-inflammatory properties under reformulation development.
Form 13D is SEC filing that must be submitted within 10 days, by anyone who acquires beneficial ownership of more than 5% of any publicly traded securities. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing. These filings may be a precursor to hostile takeovers, company breakups, and other “change of control” events.
Sparkle Byte Ltd Just Reported Giant Casi Pharmaceuticals Inc Stake - Octafinance
Sparkle Byte Ltd has filled a SC 13D form regarding Casi Pharmaceuticals, Inc . Filing Link: 000095010316010428. Per Sparkle Byte Ltd's filing, the filler now owns 13.6% of the company, holding 5,693,892 shares. CASI Pharmaceuticals Inc (NASDAQ:CASI) is a newly disclosed equity position and the filing was required due to activity on January 14, 2016.
$AMID Maintains Quarterly Distribution #Realtime @ $7.19 UP 26%
DENVER--(BUSINESS WIRE)--
American Midstream Partners, LP (AMID) today announced that the Board of Directors of its general partner declared a quarterly cash distribution of $0.4725 per common unit, or $1.89 per unit on an annualized basis. The fourth quarter 2015 distribution remains unchanged year-over-year and from the previous quarter.
The distribution will be paid February 12, 2016, to unitholders of record as of the close of business February 3, 2016, together with the general partner of American Midstream Partners, LP. The ex-dividend date is February 1, 2016.
About American Midstream Partners, LP
Denver-based American Midstream Partners, LP is a growth-oriented limited partnership formed to own, operate, develop and acquire a diversified portfolio of midstream energy assets. The Partnership provides midstream services in Texas, North Dakota, and the Gulf Coast and Southeast regions of the United States. For more information about American Midstream Partners, LP, visitwww.AmericanMidstream.com.
Forward Looking Statements
This press release includes forward-looking statements. These statements relate to, among other things, expected closing of acquisitions, growth projects, cash flows and capital expenditures. We have used the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "should," "will," "potential," and similar terms and phrases to identify forward-looking statements in this press release. Although we believe the assumptions upon which these forward-looking statements are based are reasonable, any of these assumptions could prove to be inaccurate and the forward-looking statements based on these assumptions could be incorrect. Our operations and future growth involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Actual results and trends in the future may differ materially from those suggested or implied by the forward-looking statements depending on a variety of factors which are described in greater detail in our filings with the SEC. Please see our Risk Factor disclosures included in our Annual Report on Form 10-K for the year ended December 31, 2014 filed on March 10, 2015 and our Quarterly Report on Form 10-Q for the third quarter ended September 30, 2015 filed on November 9, 2015. All future written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. The forward-looking statements herein speak as of the date of this press release. We undertake no obligation to update any information contained herein or to publicly release the results of any revisions to any forward-looking statements that may be made to reflect events or circumstances that occur, or that we become aware of, after the date of this press release.
This release serves as qualified notice to nominees as provided for under Treasury Regulation Section 1.1446-4(b)(4) and (d). Please note that 100 percent of American Midstream Partners, LP’s distributions to foreign investors are attributable to income that is effectively connected with a United States trade or business. Accordingly, all of American Midstream Partners, LP's distributions to foreign investors are subject to federal income tax withholding at the highest effective tax rate for individuals or corporations, as applicable. Nominees, and not American Midstream Partners, LP, are treated as withholding agents responsible for withholding distributions received by them on behalf of foreign investors.
American Midstream Maintains Quarterly Distribution
DENVER--(BUSINESS WIRE)-- American Midstream Partners, LP ( AMID) today announced that the Board of Directors of its general partner declared a quarterly cash distribution of $0.4725 per common unit, or $1.89 per unit on an annualized basis. The fourth quarter 2015 distribution remains unchanged year-over-year and from the previous quarter.
Why $OPTT is UP 28% #Realtime @ $2.07 ?
PENNINGTON, N.J., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. (Nasdaq:OPTT) announced today that it recently received approximately $1.7 million through the State of New Jersey's Business Tax Certificate Transfer Program (the Program).
The Program enables companies to raise cash to finance their growth and operations and is administered by the New Jersey Economic Development Authority (NJEDA) and the New Jersey Department of the Treasury's Division of Taxation. Under the Program, New Jersey-based technology and biotechnology companies with fewer than 225 US employees may be eligible to sell net operating losses (NOLs) and research and development tax credits to unaffiliated corporations up to a maximum lifetime benefit of $15 million per business.
Mark A. Featherstone, Chief Financial Officer of OPT, commented, "We appreciate NJEDA's decision to approve our application to the program again this year. As in prior years, we were fortunate to work with Public Service Enterprise Group (PSEG) on the sale of our NOLs and research and development tax credits. We appreciate the continued support of technology companies like OPT by both the State of New Jersey and PSEG. This program continues to make an important contribution to our on-going technology development efforts."
About Ocean Power Technologies
Headquartered in Pennington, New Jersey, Ocean Power Technologies (Nasdaq:OPTT) is a pioneer in renewable wave-energy technology that converts ocean wave energy into electricity. OPT's proprietary PowerBuoy® technology is based on a modular design and has undergone periodic ocean testing since 1997. OPT specializes in cost-effective and environmentally sound ocean wave based power generation and management technology.
Forward-Looking Statements
This release may contain "forward-looking statements" that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by certain words or phrases such as "may", "will", "aim", "will likely result", "believe", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", "seek to", "future", "objective", "goal", "project", "should", "will pursue" and similar expressions or variations of such expressions. These forward-looking statements reflect the Company's current expectations about its future plans and performance. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the Company. Please refer to the Company's most recent Forms 10-Q and 10-K and subsequent filings with the SEC for a further discussion of these risks and uncertainties. The Company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.
Ocean Power Technologies Receives Approximately $1.7 Million Through New Jersey''s Technology Business Tax Certificate Transfer Program - NASDAQ.com
By GlobeNewswire, January 25, 2016, 09:25:00 AM EDT PENNINGTON, N.J., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. (Nasdaq: OPTT) announced today that it recently received approximately $1.7 million through the State of New Jersey's Business Tax Certificate Transfer Program (the Program).
Subscribe to:
Posts (Atom)
Powered By
Find Out MORE